Liquidity & Technicals
Liquidity & Technicals
DAQO is institutionally tradable but size-aware — a fund can build a 1% market-cap position within 5 days at 20% ADV participation. The tape is bearish: price sits below the 200-day SMA following a death cross on March 16, 2026, at the 28th percentile of its 52-week range. The dominant technical feature is a stock trading on policy headlines, not earnings momentum.
5-Day Capacity ($M, 20% ADV)
5-Day Cap (% Mkt Cap)
Max Fund AUM @ 5% Wt ($M)
ADV 20d (% Mkt Cap)
Technical Score (-3 to +3)
Liquidity supports a mid-size fund position, but the death cross (March 2026) and bearish momentum argue for patience. The stock is a policy catalyst play — wait for the June 2026 price guidance before building size.
Price Snapshot
Current Price
YTD Return
1Y Return
52-Week Position
Beta
Critical Chart: Price History with Moving Averages
DQ's lifetime price action tells the full commodity cycle: IPO at $10 (2010), near-death at $1.50 (2012), recovery to $12 (2017), pandemic-era boom to $57 (2020), and secular decline to $19 today. Current price is below the 200-day SMA — bearish regime. The most recent death cross occurred March 16, 2026, after the stock failed to hold its Q4 2025 rally above $30.
Death cross on March 16, 2026. Price crossed below 200-day SMA after failing to sustain the Q4 2025 policy-driven rally.
Relative Strength
DQ has massively underperformed the broad market. Over the past 3 years, SPY gained roughly 35% while DQ declined approximately 50%. The relative strength gap has widened since Q1 2026 as the broader market stabilized while DQ collapsed on the Q1 FY2026 revenue miss ($27M vs prior quarter's $222M).
This persistent underperformance reflects a stock driven by a single commodity price in a structural oversupply, not a correlated market beta play. Relative strength will only inflect on industry-specific catalysts (price floors, competitor exits), not broad market risk appetite.
Momentum
Momentum is bearish. The Q4 FY2025 rally from ~$17 to ~$35 (July–November 2025) was driven by anti-involution policy optimism and the return to positive gross margins. That momentum reversed sharply after Q1 FY2026 earnings revealed near-zero revenue.
RSI is likely in the 35-40 range — approaching oversold but not yet at levels that historically triggered bounces. MACD histogram turned negative in early 2026 and has not recovered.
Volume, Volatility, and Sponsorship
Volume spikes cluster around policy events, not earnings. The 8x volume spike on October 28, 2024 (+14.1%) was entirely reversed the next day (-22.8%) — classic headline-driven volatility. The median daily range of 1.6% over 60 days is manageable for institutional execution but not negligible.
The stock is a low-conviction hold for most institutional investors. Volume has trended lower from 2023-2026, suggesting institutional sponsorship is thinning, not building.
Institutional Liquidity Panel
ADV 20d (Shares)
ADV 20d ($M)
ADV 60d (Shares)
ADV / Mkt Cap (%)
Annual Turnover (%)
A 1% market-cap position (~$13M) clears in 5 days at 20% ADV participation. A fund with under $300M AUM can take a 5% portfolio weight without liquidity constraints. Above $300M AUM, this stock becomes a sizing headache. Median daily range of 1.6% keeps impact cost manageable.
Technical Scorecard
Stance: Bearish on 3-6 month horizon. The tape confirms the fundamental story — a loss-making commodity producer with no near-term earnings catalyst. Price would need to reclaim $25 (above the 200-day SMA and prior resistance) on above-average volume to signal a regime change worth acting on. Below $13 (52-week low), the thesis breaks entirely and the market is pricing in balance-sheet deterioration. The next catalytic event is the June 2026 price guidance — if enforced, expect a sharp move above $25; if not, expect a test of $13-15 support. Liquidity is not the primary constraint for most fund sizes, but the lack of institutional sponsorship means price discovery is thin and headline-driven.